[go: up one dir, main page]

HK1091112A1 - 增加神经元的化合物及方法 - Google Patents

增加神经元的化合物及方法 Download PDF

Info

Publication number
HK1091112A1
HK1091112A1 HK06104339.6A HK06104339A HK1091112A1 HK 1091112 A1 HK1091112 A1 HK 1091112A1 HK 06104339 A HK06104339 A HK 06104339A HK 1091112 A1 HK1091112 A1 HK 1091112A1
Authority
HK
Hong Kong
Prior art keywords
cells
neurogenesis
agent
camp
receptor
Prior art date
Application number
HK06104339.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1091112B (zh
Inventor
Göran BERTILSSON
Rikard Erlandsson
Jonas Frisen
Anders Haegestrand
Jessica Heidrich
Kristina Hellstrom
Johan Haggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna FRÄMME
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Ronnholm
Olof Zachrisson
Lilian Wikstrom
Original Assignee
Newron Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1091112(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Sweden Ab filed Critical Newron Sweden Ab
Publication of HK1091112A1 publication Critical patent/HK1091112A1/zh
Publication of HK1091112B publication Critical patent/HK1091112B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
HK06104339.6A 2002-11-20 2003-11-20 增加神经元的化合物及方法 HK1091112B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42791202P 2002-11-20 2002-11-20
US60/427,912 2002-11-20
PCT/IB2003/005311 WO2004045592A2 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis

Publications (2)

Publication Number Publication Date
HK1091112A1 true HK1091112A1 (zh) 2007-01-12
HK1091112B HK1091112B (zh) 2011-10-07

Family

ID=

Also Published As

Publication number Publication date
JP5420813B2 (ja) 2014-02-19
PT1583541E (pt) 2011-04-06
JP2006514630A (ja) 2006-05-11
CY1111386T1 (el) 2015-08-05
DK1583541T3 (da) 2011-04-11
AU2003280117B2 (en) 2009-09-10
CA2506850C (en) 2014-05-13
SI1583541T1 (sl) 2011-08-31
WO2004045592A2 (en) 2004-06-03
EP1583541A2 (en) 2005-10-12
JP5421194B2 (ja) 2014-02-19
ATE494904T1 (de) 2011-01-15
US20050009847A1 (en) 2005-01-13
DE60335743D1 (de) 2011-02-24
CA2506850A1 (en) 2004-06-03
EP1583541B1 (en) 2011-01-12
ES2359720T3 (es) 2011-05-26
AU2003280117A1 (en) 2004-06-15
JP2010195841A (ja) 2010-09-09
WO2004045592A3 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
EP1583541B1 (en) Compounds and methods for increasing neurogenesis
US6969702B2 (en) Compounds and methods for increasing neurogenesis
US20090232775A1 (en) Compounds and methods for increasing neurogenesis
CA2546843C (en) Compounds and methods for increasing neurogenesis
Heinrich et al. Reelin deficiency and displacement of mature neurons, but not neurogenesis, underlie the formation of granule cell dispersion in the epileptic hippocampus
AU776265B2 (en) Methods and compositions for treating or preventing peripheral neuropathies
US20040038888A1 (en) Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells
US7138492B2 (en) Method of treating dopaminergic and GABA-nergic disorders
HK1091112B (zh) 增加神经元的化合物及方法
Bertilsson Compounds and methods for increasing neurogenesis
US20030162698A1 (en) Methods and compositions for treating dopaminergic and gaba-nergic disorders
AU763032B2 (en) Methods and compositions for treating disorders involving excitotoxicity
US20040220096A1 (en) Method and compositions for treating dopaminergic and gabanergic disorders
WO2004105787A1 (en) Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
Vaudry et al. 7th International Symposium on VIP, PACAP and Related Peptides Rouen, France September, 11–14, 2005
US20080221037A1 (en) Methods and compositions for treating disorders involving excitotoxicity
Miranda-Angulo TRANSCRIPTIONAL CONTROL OF HYPOTHALAMIC TANYCYTE DEVELOPMENT

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181118